*Study design: Of the patients who rolled over from the HALO studies, 611 from the HALO CM study (quarterly, n=306; monthly, n=305) and 432 from the HALO EM study (quarterly, n=217; monthly, n=215) had received AJOVY during the respective HALO study and were included in the post hoc analysis during the long-term open-label extension study.1
You had searched for:
There were no results matching the query.
You can also browse the topics below to find what you are looking for.
For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.
Select the data:
4.0 mean baseline weekly migraine days
2.3 mean baseline weekly migraine days